OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / ...
U.S. consumers who have had their fill of protein-enhanced cereal and ice cream are about to meet the next big food fad. It's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback